Connect with us

Media & Technology

BioElectronics Corp. (OTCPINK: BIEL) Major Reversal Brewing as Pain Management Pioneer Reports Record Revenues & Readies Launch of its KT Recovery+ WaveTM in the UK

Published

on

BioElectronics Corp. (OTCPINK: BIEL) is heating up in recent trading and signaling it may be ready for a major reversal northbound off $0.001 support levels. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board.  The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere as so many penny stocks did last year  – a break over $0.008 and its blue skies ahead for BIEL. 

BIEL sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year. BioElectronics is making big moves and quickly gaining traction in an enormous market; chronic pain affects approximately 1.5 billion people globally – more than heart disease, cancer, and diabetes. Chronic pain costs $700 billion annually in the US and Europe alone. BioElectronics product line of drug-free pain relievers meets these needs and is ready to seize this global opportunity. The Company has received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®.  These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).  

BioElectronics Corp. (OTCPINK: BIEL) is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative pain and wound care.  In February 2017, BioElectronics received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain. More recently BIEL received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®.  These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).  

BIEL current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use.  

The Company has a partnership with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer marketplace under the DonJoy® BIEL also has an OEM agreement in place with KT Health, LLC that incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. KT Health, LLC recently received its initial order to launch its KT Recovery+ WaveTM in the United Kingdom and intends to continue expansion into other markets. Sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year. 

To Find out the inside Scoop on BIEL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEL

BioElectronics continues making progress on international sales; the Company’s sales partner in Australia, LMT Surgical Party, Ltd, is reporting strong demand and excellent clinical outcomes with the RecoveryRx product.  BioElectronics sales partner in Korea is preparing to receive their first order with an expected product launch date in the spring of 2022.  The Company’s distributor in Bangladesh has resumed full operations following Covid19 shutdowns in Bangladesh and has placed an order for delivery in the first quarter of 2022.  The sales team continues discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region. The sales team is also actively seeking an OEM partner for a wound pain product development partnership.  

The Research and Development team is expanding its efforts regarding the brain stimulation project by collaborating with the Clinical Science and Engineering Research Lab at Binghamton University under the guidance of Ken McLeod, Ph.D.  The vision behind this research undertaking is to develop and optimize PSWT technology that will be capable of serving as a therapeutic intervention for psychological disorders such as depression and anxiety. 

On January 3, 2021 BIEL announced the managers of the firm’s two largest lenders, Ibex LLC and St. John’s LLC, both of which are controlled by Whelan family members, have agreed to forgo interest due on their convertible debt notes for a third consecutive year, through the end of 2022. Kelly Whelan, President & CEO of BioElectronics, stated: “It is the goal of both the BioElectronics’ management team and the Whelan family to bring the Company to sustained profitability as quickly as possible, for the benefit of all shareholders. The Whelan family has collectively forfeited interest in excess of $1.5 million during 2020 and 2021 and will extend forbearance of interest through at least 2022.”  

BIEL continues its engagements in basic and applied research embarking on 3 new projects over the past 6 months. The Company is also actively seeking partners towards its goal of expanding its technology’s indications for use. Specifically, the goal is to put together a basic and applied research plan for various clinical disorders that are closely linked to the etiology behind many types of chronic pain, i.e. central sensitization. Some of these disorders include, but are not limited to, overactive bladder (about 33 million Americans have overactive bladder), vulvodynia (as many as 16 percent of women in the U.S. suffer from vulvodynia at some point in their lives), and other treatment-resistant conditions.  

BioElectronics is making big moves and quickly gaining traction in en enormous market; chronic pain affects approximately 1.5 billion people globally – more than heart disease, cancer, and diabetes. Chronic pain costs $700 billion annually in the US and Europe. BioElectronics product line of drug-free pain relievers meets these needs and is ready to seize this global opportunity. BIEL has the right people behind it; the Company is led by CEO Andrew Whelan whose family is BioElectronics biggest creditor and their EVP Dr. Deepak Kotak who was chief medical officer at Houston based TraumaTec. Dr. Kotak has also practiced for four years as a civil lawyer. He has a particular interest in therapeutic vaccines for cancer and chronic infectious diseases.

For More on BIEL Subscribe Right Now!

BIEL is heating up in recent trading and signaling it may be ready for a major reversal northbound off $0.001 support levels. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board.  The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere as so many penny stocks did last year  – a break over $0.008 and its blue skies ahead for BIEL. BIEL sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year. BioElectronics is making big moves and quickly gaining traction in an enormous market; chronic pain affects approximately 1.5 billion people globally – more than heart disease, cancer, and diabetes. Chronic pain costs $700 billion annually in the US and Europe alone. BioElectronics product line of drug-free pain relievers meets these needs and is ready to seize this global opportunity. The Company has received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®.  These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). We will be updating on BIEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in  BIEL either long or short and we have not been compensated for this article

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.